March 5, 2026
TOPLINE: Among patients who were eligible for metabolic and bariatric surgery in a national sample in the US, prescriptions for semaglutide and tirzepatide increased dramatically from […]
March 5, 2026
* Through the Lilly Employer Connect platform, itsmulti-dose weight-loss drug device Zepbound KwikPen will beavailable to network pharmacies at a discounted price of $449for all doses […]
March 5, 2026
TOPLINE: Researchers developed and validated a machine learning model based on logistic regression that used routine clinical and treatment data to accurately predict in-hospital deaths among […]
March 4, 2026
TOPLINE: A notable proportion of older adults with inflammatory bowel disease (IBD) screened positive for cognitive impairment at baseline in this longitudinal cohort study. Symptomatically active […]
March 3, 2026
Increased serum antibody response to commensal Lachnospiraceae flagellins appears to be preclinically associated with future risk for Crohn’s disease (CD) in healthy first-degree relatives (FDRs) of […]
March 2, 2026
Nausea. Constipation. Diarrhea. Heartburn. These are the annoying side effects that GLP-1 users complain about most often — and sometimes prompt them to discontinue the medications. […]
March 2, 2026
In patients with unexplained acute recurrent pancreatitis who have pancreas divisum, the widely used procedure endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy does not reduce the […]
February 27, 2026
TOPLINE: Among adults with obesity and type 2 diabetes (T2D), metabolic and bariatric surgery reduced the risk for major adverse cardiovascular events by more than 50% […]
February 27, 2026
TOPLINE: Among patients with Crohn’s disease, risankizumab yielded significant improvements in clinical and endoscopic outcomes and had a favourable safety profile; prior ustekinumab exposure was associated […]